FrancophonIA/ELRC3.0 huggingface dataset:
English: Adverse events are listed below by system organ class and frequency.
Croatian: Niže navedene nuspojave su navedene prema tjelesnom sustavu i učestalosti.
English: • if you are allergic (hypersensitive) to orlistat or to any of the other ingredients of Xenical,
Croatian: • ako ste alergični (preosjetljivi) na orlistat ili na bilo koji drugi sastojak lijeka Xenical, • ako imate kronični malapsorpcijski sindrom (nedovoljna apsorpcija hranjivih tvari iz probavnog sustava),
English: Overall, after one year of treatment, the percentage of patients taking 120 mg orlistat who lost 10 % or more of their body weight was 20 % with orlistat 120 mg compared to 8 % of patients taking placebo.
Croatian: Sveukupno, nakon jedne godine liječenja, postotak bolesnika koji su izgubili 10 % ili više tjelesne težine iznosio je 20 % onih liječenih dozom od 120 mg orlistata u odnosu na 8 % bolesnika liječenih placebom.
English: The main symptoms are itching, rash, wheals (slightly elevated, itchy skin patches that are paler or redder than surrounding skin), severe difficulty in breathing, nausea, vomiting and feeling unwell.
Croatian: Alergijske reakcije čiji su glavni simptomi svrbež, osip, urtike (blago uzdignuti dijelovi kože koji svrbe i koji su bljeđi ili crveniji od okolne kože), jako otežano disanje, mučnina, povraćanje i loše osjećanje.
English: Capsule filling: microcrystalline cellulose (E460) sodium starch glycolate (type A) povidone (E1201) sodium laurilsulfate talc
Croatian: Sadržaj kapsule: celuloza, mikrokristalična (E460) natrijev škroboglikolat (tip A) povidon (E1201) natrijev laurilsulfat talk
English: Pancreatitis (inflammation of the pancreas).
Croatian: Pankreatitis (upala gušterače).
English: The incidence of adverse events decreased with prolonged use of orlistat.
Croatian: Incidencija nuspojava smanjuje se što je liječenje orlistatom duže.
English: MARKETING AUTHORISATION NUMBERS EU/1/98/071/001-006
Croatian: ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/98/071/001-006
English: Rare occurrence of hypothyroidism and/or reduced control of hypothyroidism may occur.
Croatian: Rijetko može nastati hipotireoza i/ili smanjena kontrola hipotireoze.
English: Antiepileptics patient: Orlistat may unbalance anticonvulsivant treatment by decreasing the absorption of antiepileptic drugs, leading to convulsions (see section 4.5).
Croatian: Bolesnici s epilepsijom: orlistat može narušiti ravnotežu antikonvulzivne terapije smanjenjem apsorpcije antiepileptika, što dovodi do konvulzija (vidjeti dio 4.5).
English: The daily intake of fat should be distributed over three main meals.
Croatian: Dnevni unos masti potrebno je raspodijeliti na sva tri glavna obroka.
English: Hypersensitivity (e.g. pruritus, rash, urticaria, angioedema, bronchospasm and anaphylaxis)
Croatian: Poremećaji imunološkog sustava reakcije preosjetljivosti (npr. svrbež, osip, urtikarija, angioedem, bronhospazam i anafilaksija)
English: Rectal bleeding Diverticulitis Pancreatitis
Croatian: Poremećaji probavnog sustava rektalno krvarenje divertikulitis pankreatitis
English: Bottles: Do not store above 30 °C.
Croatian: Boce: Ne čuvati na temperaturi iznad 30°C.
English: The great majority of diabetes cases came from the subgroup of patients with impaired glucose tolerance at baseline, which represented 21 % of the randomised patients.
Croatian: Velika većina slučajeva razvoja dijabetesa pojavila se u skupini bolesnika koji su već na početku liječenja imali poremećaj tolerancije glukoze, a koja je sačinjavala 21 % randomiziranih bolesnika.
English: In addition, doses of 240 mg tid have been administered to obese patients for 6 months.
Croatian: pretilim bolesnicima primjenjivane su doze od 240 mg tri puta dnevno u trajanju od 6 mjeseci.
English: Cases of hypothyroidism and/or reduced control of hypothyroidism may occur.
Croatian: Može doći do hipotireoze i/ili smanjene kontrole hipotireoze.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR BLISTER PACKS
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA BLISTERE
English: If you have further questions on the use of this medicine, ask your doctor or pharmacist.
Croatian: U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka obratite se svom liječniku ili ljekarniku.
English: Adverse reactions to orlistat are largely gastrointestinal in nature.
Croatian: 4.8 Nuspojave Nuspojave orlistata uglavnom su gastrointestinalne naravi.
English: A slight decrease in plasma levels of amiodarone, when given as a single dose, has been observed in a limited number of healthy volunteers who received orlistat concomitantly.
Croatian: Nakon primjene jednokratne doze amiodarona, na ograničenom broju zdravih dobrovoljaca koji su istodobno primili orlistat, primijećeno je neznatno sniženje koncentracije amiodarona u plazmi.
English: In orlistat-treated patients, the mean difference from placebo in weight loss was 1.83 kg to 3.06 kg and the mean difference from placebo in HbA1c reduction was 0.18 % to 0.55 %.
Croatian: 3,06 kg, a srednja razlika u smanjenju HbA1c u odnosu na placebo 0,18 % do 0,55%.
English: Keep container tightly closed in order to protect from moisture.
Croatian: Spremnik čuvati čvrsto zatvoren radi zaštite od vlage.
English: Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Croatian: embrionalni/fetalni razvoj, okot ili postnatalni razvoj (vidjeti dio 5.3).
English: Do not use Xenical after the expiry date stated on the carton.
Croatian: Xenical se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji.
English: Prescribers should investigate further in case of severe and/or persistent symptoms.
Croatian: U slučaju teških i/ili dugotrajnih simptoma liječnik treba podrobnije ispitati uzroke.
English: Normally, these symptoms disappear if you continue treatment and keep to your recommended diet.
Croatian: Nastavkom liječenja i ako se pridržavate preporučene prehrane ti simptomi obično nestanu.
English: Metabolism and nutrition disorders Very common: Hypoglycemia*
Croatian: Vrlo često: hipoglikemija*
English: Of these, 62 % of orlistat treated patients and 52 % of placebo treated patients went on to lose ≥ 10 % of their baseline body weight at one year.
Croatian: Od navedenog, 62 % bolesnika liječenih orlistatom i 52 % bolesnika liječenih placebom izgubilo je ≥ 10% njihove početne tjelesne težine nakon jedne godine.
English: • Anticoagulant drugs (e.g. warfarin).
Croatian: • lijekova protiv zgrušavanja krvi (npr. varfarina).
English: Your doctor will discontinue the treatment with Xenical after 12 weeks if you have not lost at least 5 % of your body weight as measured at the start of treatment with Xenical.
Croatian: Vaš će liječnik obustaviti liječenje lijekom Xenical nakon 12 tjedana ako niste izgubili barem 5%
English: How to take XENICAL
Croatian: Kako uzimati XENICAL
English: Blisters: Do not store above 25 °C.
Croatian: Blisteri: Ne čuvati na temperaturi iznad 25°C.
English: Headache, abdominal pain/discomfort, urgent or increased need to open the bowels, flatulence (wind) with discharge, oily discharge, oily or fatty stools, liquid stools, low blood sugar levels (experienced by some people with type 2 diabetes).
Croatian: Vrlo česte nuspojave (javljaju se kod više od 1 na 10 korisnika) Glavobolja, bol/nelagoda u trbuhu, hitna ili povećana potreba za pražnjenjem crijeva, vjetrovi s istjecanjem stolice, uljasti iscjedak, uljaste ili masne stolice, tekuće stolice, niska razina šećera u krvi (kod nekih osoba oboljelih od dijabetesa tipa 2)
English: Data from the 4-year XENDOS clinical trial showed that 60 % of orlistat patients and 35 % of placebo patients demonstrated a loss of at least 5 % of their baseline body weight after 12 weeks of treatment.
Croatian: Podaci iz četverogodišnjeg kliničkog ispitivanja XENDOS pokazali su da je nakon 12 tjedana liječenja kod 60 % bolesnika liječenih orlistatom i 35 % bolesnika liječenih placebom došlo do gubitka barem 5 % njihove početne tjelesne težine.
English: Xenical reduces the absorption of supplements of some fat soluble nutrients, particularly beta-carotene and vitamin E. You should therefore follow your doctor's advice in taking a well balanced diet rich in fruit and vegetables.
Croatian: Xenical smanjuje apsorpciju pripravaka nekih tvari topivih u masti, osobito beta-karotena i vitamina E.
English: Hepatitis that may be serious.
Croatian: Poremećaji jetre i žuči kolelitijaza Hepatitis koji može biti ozbiljan.
English: Therefore, if you miss a main meal or if you have a meal containing no fat, Xenical need not be taken.
Croatian: Prema tome, nije ga potrebno uzeti ako preskočite glavni obrok ili ako pojedete obrok koji ne sadrži masnoće.
English: Decreased prothrombin, increased INR and unbalanced anticoagulant treatment resulting in variations of haemostatic parameters have been reported in patients treated with anticoagulants in association with orlistat (see section 4.4 and 4.5)
Croatian: U bolesnika istovremeno liječenih antikoagulansima i orlistatom prijavljeni su sniženi protrombin, povišeni INR i neuravnoteženo antikoagulacijsko liječenje, koji su doveli do varijacija hemostatskih parametara (vidjeti dio 4.4 i 4.5)
English: NAME OF THE MEDICINAL PRODUCT Xenical 120 mg hard capsules
Croatian: NAZIV LIJEKA Xenical 120 mg tvrde kapsule
English: However, orlistat may indirectly reduce the availability of oral contraceptives and lead to unexpected pregnancies in some individual cases.
Croatian: Međutim, orlistat može indirektno smanjiti raspoloživost oralnih kontraceptiva,
English: How to store Xenical
Croatian: Kako čuvati XENICAL
English: The use of orlistat may be associated with hyperoxaluria and oxalate nephropathy leading sometimes to renal failure.
Croatian: Primjena orlistata može biti povezana s hiperoksalurijom i nefropatijom uzrokovanom oksalatima,
English: Data from the 4-year clinical trial also suggested that weight loss achieved with orlistat delayed the development of type 2 diabetes during the study (cumulative diabetes cases incidences: 3.4 % in the orlistat group compared to 5.4 % in the placebo-treated group).
Croatian: odgodio razvoj dijabetesa tipa II za vrijeme trajanja ispitivanja (kumulativna incidencija slučajeva dijabetesa: 3,4 % u skupini koja je primala orlistat, u odnosu na 5,4 % u skupini koja je primala placebo).
English: Rectal pain/discomfort, soft stools, incontinence (stools), bloating (experienced by some people with type 2 diabetes), tooth/gum disorder, irregularity of menstrual cycle, tiredness.
Croatian: Česte nuspojave (javljaju se kod 1 do 10 na 100 korisnika) Bol/nelagoda u rektumu, mekane stolice, inkontinencija (stolice), osjećaj nadutosti (kod nekih osoba oboljelih od dijabetesa tipa 2), poremećaji zuba/desni, nepravilan menstrualni ciklus, umor.
English: Pooled data from five 2 year studies with orlistat and a hypocaloric diet showed that 37 % of orlistat patients and 19 % of placebo patients demonstrated a loss of at least 5 % of their baseline body weight after 12 weeks of treatment.
Croatian: Podaci prikupljeni iz pet studija u trajanju od po dvije godine, u kojima se ispitivao orlistat i hipokalorijska dijeta, pokazali su da je nakon 12 tjedana liječenja kod 37 % bolesnika liječenih orlistatom i 19 % bolesnika liječenih placebom došlo do gubitka barem 5 % početne tjelesne težine.
English: NAME OF THE MEDICINAL PRODUCT Xenical 120 mg hard capsules Orlistat
Croatian: NAZIV LIJEKA Xenical 120 mg tvrde kapsule orlistat
English: EU/1/98/071/005 42 capsules
Croatian: EU/1/98/071/005 42 kapsule
English: Abdominal pain/discomfort Oily spotting from the rectum Flatus with discharge Faecal urgency Fatty/oily stool Flatulence
Croatian: abdominalna bol/nelagoda masni iscjedak iz rektuma vjetrovi s istjecanjem stolice hitne stolice masna/uljasta stolica flatulencija tekuće stolice uljasto pražnjenje povećana defekacija rektalna bol/nelagoda mekane stolice fekalna inkontinencija distenzija abdomena*
English: EU/1/98/071/006 84 capsules
Croatian: EU/1/98/071/006 84 kapsule
English: More patients on orlistat or placebo lost baseline body weight of at least 5 % at 12 weeks or 10 % at one year in the XENDOS study than in the five 2-year studies.
Croatian: 12 tjedana ili 10 % nakon jedne godine u studiji XENDOS nego u pet dvogodišnjih studija.
English: Single doses of 800 mg orlistat and multiple doses of up to 400 mg three times daily for 15 days have been studied in normal weight and obese subjects without significant adverse findings.
Croatian: 4.9 Predoziranje Ispitivanje jednokratnih doza od 800 mg orlistata i višestrukih doza do 400 mg tri puta dnevno tijekom
English: The mechanism, although not proven, may involve a decreased absorption of iodine salts and/or levothyroxine (see section 4.5).
Croatian: može uključiti smanjenu apsorpciju soli joda i/ili levotiroksina (vidjeti dio 4.5).
English: Read the package leaflet before use
Croatian: Prije uporabe pročitati Uputu o lijeku
English: Coagulation parameters should be monitored in patients treated with concomitant oral anticoagulants (see section 4.5 and 4.8).
Croatian: U bolesnika istodobno liječenih antikoagulansima treba pratiti parametre koagulacije (vidjeti dio 4.5 i
English: MARKETING AUTHORISATION NUMBER(S) EU/1/98/071/004 21 capsules
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/98/071/004 21 kapsula
English: Conversely, of patients failing to demonstrate a loss of 5 % of their baseline body weight after 12 weeks of treatment, only 5 % of orlistat treated patients and 4 % of placebo treated patients went on to lose ≥ 10 % of their baseline body weight at one year.
Croatian: Nasuprot tome, u bolesnika koji nakon 12 tjedana liječenja nisu izgubili barem 5 % njihove početne tjelesne težine, samo je 5 % bolesnika liječenih orlistatom i 4 % bolesnika liječenih placebom izgubilo ≥ 10 % njihove početne tjelesne težine nakon jedne godine.
English: Conversely, of patients failing to demonstrate a loss of 5 % of their baseline body weight after 12 weeks of treatment, only 5 % of orlistat treated patients and 2 % of placebo treated patients went on to lose ≥ 10 % of their baseline body weight at one year.
Croatian: Nasuprot tome, u bolesnika koji nakon 12 tjedana liječenja nisu izgubili barem 5 % početne tjelesne težine, samo je 5 % bolesnika liječenih orlistatom i 2 % bolesnika liječenih placebom izgubilo ≥ 10 % njihove početne tjelesne težine nakon jedne godine.
English: 9.5 % of the orlistat treated patients versus 3.3 % of the placebo treated patients lost ≥ 10 % of body weight after 1 year with a mean difference of 2.6 kg between the two groups.
Croatian: Nakon jedne godine liječenja 9,5 % bolesnika liječenih orlistatom i 3,3 % bolesnika liječenih placebom izgubilo je ≥ 10% tjelesne težine, uz srednju razliku u gubitku težine između te dvije skupine od 2,6 kg.
English: After 1 year of treatment, 41 % of the orlistat treated patients versus 21 % of placebo treated patients lost ≥ 10 % of body weight with a mean difference of 4.4 kg between the two groups.
Croatian: Nakon jedne godine liječenja 41 % bolesnika liječenih orlistatom i 21 % bolesnika liječenih placebom izgubilo je ≥ 10 % tjelesne težine, uz srednju razliku u gubitku težine između te dvije grupe od 4,4 kg.
English: NAME OF THE MARKETING AUTHORISATION HOLDER CHEPLAPHARM Arzneimittel GmbH
Croatian: 11. IME I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET CHEPLAPHARM Arzneimittel GmbH
English: Do not store above 25 °C
Croatian: Ne čuvati na temperaturi iznad 25°C
English: An additional contraceptive method is recommended in case of severe diarrhoea (see section 4.4).
Croatian: U slučaju teškog proljeva preporučuje se dodatna metoda kontracepcije (vidjeti dio 4.4) 4.6 Plodnost, trudnoća i dojenje
English: • The other ingredients are microcrystalline cellulose (E460), sodium starch glycolate (type A), povidone (E1201), sodium laurilsulfate and talc.
Croatian: • Pomoćne tvari su mikrokristalična celuloza (E460), natrijev škroboglikolat (tip A), povidon
English: After 4 years of treatment 21 % of the orlistat treated patients compared to 10 % of the placebo treated patients had lost ≥ 10 % of body weight, with a mean difference of 2.7 kg.
Croatian: Nakon četiri godine liječenja, 21 % bolesnika liječenih orlistatom i 10 % bolesnika liječenih placebom izgubilo je ≥ 10 % tjelesne težine, uz srednju razliku u gubitku težine između te dvije grupe od 2,7 kg.
English: Marketing Authorisation Holder CHEPLAPHARM Arzneimittel GmbH Ziegelhof 24
Croatian: NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET CHEPLAPHARM Arzneimittel GmbH Ziegelhof 24
English: 4.7 Effects on ability to drive and use machines
Croatian: 4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Xenical ne utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Therefore the combination is not recommended (see section 4.4).
Croatian: (vidjeti dio 4.4).
English: The use of an additional contraceptive method is recommended to prevent possible failure of oral contraception that could occur in case of severe diarrhoea (see section 4.5).
Croatian: Kako uz teški proljev oralna kontracepcija može biti neučinkovita, u tom se slučaju preporučuje uporaba dodatne metode kontracepcije (vidjeti dio 4.5).
English: * only unique treatment adverse events that occurred at a frequency of > 2 % and with an incidence ≥ 1 % above placebo in obese type 2 diabetic patients.
Croatian: ≥ 1% u odnosu na placebo, u pretilih bolesnika s dijabetesom tipa II
English: Gallstones.
Croatian: Žučni kamenci.
English: Antidiabetic medicinal product treatment may have to be closely monitored when taking orlistat.
Croatian: Bolesnike koji uzimaju oralne antidijabetike i orlistat treba pomno pratiti.
English: The use of an additional contraceptive method is recommended to prevent possible failure of oral contraception that could occur in case of severe diarrhoea.
Croatian: Kako uz teški proljev oralna kontracepcija može biti neučinkovita, u tom se slučaju preporučuje uporaba dodatne metode kontracepcije.
English: Of these, 49 % of orlistat treated patients and 40 % of placebo treated patients went on to lose ≥ 10 % of their baseline body weight at one year.
Croatian: Od navedenih, 49 % bolesnika liječenih orlistatom i 40 % bolesnika liječenih placebom izgubilo je
English: A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET
English: Very common: Influenza General disorders and administration site conditions
Croatian: Vrlo često: influenca
English: How to store XENICAL
Croatian: Moguće nuspojave Kako čuvati Xenical
English: Reproductive system and breast disorders Common: Menstrual irregularity
Croatian: Poremećaji reproduktivnog sustava i dojki
English: Oxalate nephropathy that may lead to renal failure
Croatian: Poremećaji bubrega i mokraćnog sustava nefropatija uzrokovana oksalatima koja može dovesti do zatajenja bubrega
English: Keep the container tightly closed in order to protect from moisture
Croatian: Ne čuvati na temperaturi iznad 30°C Spremnik čuvajte čvrsto zatvoren radi zaštite od vlage
English: This might be every 6 to 12 months.
Croatian: To može biti svakih 6 do 12 mjeseci.
English: Your patient data will be registered anonymously- nobody will know it is information about you.
Croatian: Vaši bolesnički podaci bit će prijavljeni anonimno - nitko neće znati da se odnose na Vas.
English: Patient data will be anonymously collected in this Registry.
Croatian: Podaci o bolesnicima bit će anonimno prikupljeni u taj registar.
English: The information in this leaflet applies to all patient groups including children, adolescents, adults and the elderly.
Croatian: Informacije iz ove upute odnose se na sve skupine bolesnika, uključujući djecu, adolescente, odrasle i starije bolesnike.
English: Date of first authorisation: 17 November 1997 Date of latest renewal: 17 September 2007
Croatian: Datum prvog odobrenja: 17. studenoga 1997.
English: You may need to be given additional medicines to prevent an allergic reaction (e.g. antihistamines and/or corticosteroids).
Croatian: Možda ćete trebati dodatne lijekove kako bi se spriječila alergijska reakcija (npr. antihistaminike i/ili kortikosteroide).
English: The usual frequency of infusion is once every 2 weeks (see section 4.2).
Croatian: Uobičajena učestalost davanja infuzije je jedanput svaka 2 tjedna (vidjeti dio 4.2).
English: • hepatomegaly or splenomegaly
Croatian: • hepatomegaliju ili splenomegaliju
English: Your doctor will work out your dose based on how severe your symptoms are, and other factors.
Croatian: Liječnik će odrediti Vašu dozu na temelju težine simptoma i drugih čimbenika.
English: Other medicines and Cerezyme
Croatian: Drugi lijekovi i Cerezyme
English: • anaemia after exclusion of other causes, such as iron deficiency
Croatian: • anemiju, nakon isključenja drugih uzroka kao što je nedostatak željeza
English: The cause can be unknown, or it can be due to heart, lung or liver problems.
Croatian: Uzrok može biti nepoznat ili može nastati zbog problema sa srcem, plućima ili jetrom.
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity and genotoxicity.
Croatian: Neklinički podaci ne upućuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti jednokratnih i ponovljenih doza i genotoksičnosti.
English: Please contact your doctor if you would like to be treated at home.
Croatian: Obratite se liječniku ako se želite liječiti kod kuće.
English: Paediatric population No dose adjustment is necessary for the paediatric population.
Croatian: Pedijatrijska populacija Nije potrebno prilagođavati dozu pedijatrijskoj populaciji.
English: Your doctor will keep a close check on your response to your treatment, and may change your dose (up or down) until he/she finds the best dose to control your symptoms.
Croatian: Liječnik će pomno nadzirati Vaš odgovor na liječenje i možda će mijenjati dozu (povećavati je ili smanjivati) dok ne utvrdi najbolju dozu za ublažavanje Vaših simptoma.
English: Cerezyme should not be given as a mixture with other medicinal products in the same infusion (drip).
Croatian: Cerezyme se ne smije davati pomiješan s drugim lijekovima u istoj infuziji (dripu).
English: The product diluted in 0.9%
Croatian: Lijek razrijeđen u 0,9%
English: This will not lead to any loss of imiglucerase activity.
Croatian: To neće prouzročiti smanjenje aktivnosti imigluceraze.
English: These variables do not appear to be influenced by dose or duration of infusion, however, only 1 or 2 patients were studied at each dose level and infusion rate.
Croatian: Čini se da na te varijable ne utječu ni doza ni trajanje infuzije, međutim, ispitivanje je provedeno u svega 1 ili 2 bolesnika pri svakoj dozi i brzini infuzije.
English: If you use more Cerezyme than you should
Croatian: Ako primijenite više lijeka Cerezyme nego što ste trebali
English: • bone disease after exclusion of other causes such as Vitamin D deficiency
Croatian: • bolest kostiju, nakon isključenja drugih uzroka kao što je nedostatak vitamina D
English: The non-neurological manifestations of Gaucher disease include one or more of the following conditions:
Croatian: Manifestacije Gaucherove bolesti koje nisu neurološke naravi uključuju jedno ili više od navedenih stanja:
English: Educational materials for the use of Cerezyme in home infusion, consisting of:
Croatian: Edukacijski materijali za primjenu infuzije lijeka Cerezyme kod kuće, koji se sastoje od:
English: Cerezyme has no or negligible influence on the ability to drive and use machines.
Croatian: Cerezyme ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Following infusion, plasma enzymatic activity declined rapidly with a half-life ranging from 3.6 to 10.4 minutes.
Croatian: Nakon infuzije se enzimska aktivnost u plazmi naglo smanjila, pri čemu se poluvijek kretao u rasponu od 3,6 do 10,4 minuta.
English: The reconstituted solution must be further diluted.
Croatian: Rekonstituirana otopina mora se dodatno razrijediti.